mk 0663 has been researched along with Prostatic Neoplasms in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Andreesen, R; Berand, A; Reichle, A; Rogenhofer, S; Vogelhuber, M; Walter, B; Wieland, WF | 1 |
| Di Silverio, F; Gentile, V; Sciarra, A | 1 |
2 trial(s) available for mk 0663 and Prostatic Neoplasms
| Article | Year |
|---|---|
Modular therapy approach in metastatic castration-refractory prostate cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Bone Neoplasms; Capecitabine; Deoxycytidine; Dexamethasone; Disease Progression; Drug Therapy, Combination; Etoricoxib; Fluorouracil; Humans; Kaplan-Meier Estimate; Lactones; Male; Orchiectomy; Pioglitazone; Prostatic Neoplasms; Pyridines; Sulfones; Thiazolidinediones; Treatment Outcome | 2010 |
Etoricoxib and intermittent androgen deprivation therapy in patients with biochemical progression after radical prostatectomy.
Topics: Aged; Androgen Antagonists; Anilides; Cyclooxygenase Inhibitors; Disease Progression; Etoricoxib; Humans; Male; Middle Aged; Nitriles; Prospective Studies; Prostatectomy; Prostatic Neoplasms; Pyridines; Sulfones; Tosyl Compounds | 2008 |